Advantages and Disadvantages of Technologies for HER2 Testing in Breast Cancer Specimens: Table 1

2015/10/20 by Daniela Furrer, François Sanschagrin, Simon Jacob +1 · 90 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Advanced Biosensing Techniques and Applications #Breast Cancer Treatment Studies #Breast cancer #Cancer #Computer science #HER2/EGFR in Cancer Research #Human Epidermal Growth Factor Receptor 2 #Internal medicine #Lapatinib #Medical physics #Medicine #Oncology #Standardization #Trastuzumab

paper · pdf · doi:10.1309/ajcpt41tcbuevdqc

published in American Journal of Clinical Pathology 144(5), 686-703 (Oxford University Press)

openalex publication_date 2015/10/20 · openalex created_date 2016/06/24 · openalex updated_date 2026/08/05

Abstract

OBJECTIVES: Human epidermal growth factor receptor 2 (HER2) plays a central role as a prognostic and predictive marker in breast cancer specimens. Reliable HER2 evaluation is central to determine the eligibility of patients with breast cancer to targeted anti-HER2 therapies such as trastuzumab and lapatinib. Presently, several methods exist for the determination of HER2 status at different levels (protein, RNA, and DNA level). METHODS: In this review, we discuss the main advantages and disadvantages of the techniques developed so far for the evaluation of HER2 status in breast cancer specimens. RESULTS: Each technique has its own advantages and disadvantages. It is therefore not surprising that no consensus has been reached so far on which technique is the best for the determination of HER2 status. CONCLUSIONS: Currently, emphasis must be put on standardization of procedures, internal and external quality control assessment, and competency evaluation of already existing methods to ensure accurate, reliable, and clinically meaningful test results. Development of new robust and accurate diagnostic assays should also be encouraged. In addition, large clinical trials are warranted to identify the technique that most reliably predicts a positive response to anti-HER2 drugs.

Cited by

• Multicenter Study Using Desorption-Electrospray-Ionization-Mass-Spectrometry Imaging for Breast-Cancer Diagnosis. [europepmc]
• Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors. [europepmc]
• Correlation between HER2 Expression and Clinicopathological Features of Breast Cancer: A Cross- Sectional Study in Vietnam. [europepmc]
• Genome oligopaint via local denaturation fluorescence in situ hybridization. [europepmc]
• A photocleavable peptide-tagged mass probe for chemical mapping of epidermal growth factor receptor 2 (HER2) in human cancer cells. [europepmc]
• Liquid Biopsy and Tissue Biopsy Comparison with Digital PCR and IHC/FISH for HER2 Amplification Detection in Breast Cancer Patients. [europepmc]
• MDM2 Gene Amplification and Expression of MDM2 and CDK4 are Rare in Ossifying Fibroma of Craniofacial Bones. [europepmc]
• Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions. [europepmc]
• Singular Nuclei Segmentation for Automatic HER2 Quantification Using CISH Whole Slide Images. [europepmc]
• Label-Free Optical Spectroscopy for Early Detection of Oral Cancer. [europepmc]
• Demystifying the Role of Prognostic Biomarkers in Breast Cancer through Integrated Transcriptome and Pathway Enrichment Analyses. [europepmc]
• Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial. [europepmc]
• Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects. [europepmc]
• HER2 copy number determination in breast cancer using the highly sensitive droplet digital PCR method. [europepmc]
• Think "HER2" different: integrative diagnostic approaches for HER2-low breast cancer. [europepmc]
• Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab. [europepmc]
• High contrast breast cancer biomarker semi-quantification and immunohistochemistry imaging using upconverting nanoparticles. [europepmc]
• High HER2 Intratumoral Heterogeneity Is a Predictive Factor for Poor Prognosis in Early-Stage and Locally Advanced HER2-Positive Breast Cancer. [europepmc]
• Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines. [europepmc]
• Consensus Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2)-Low Testing in Breast Cancer in Malaysia. [europepmc]
• Current status and challenges in HER2 IHC assessment: scoring survey results in Japan. [europepmc]
• Development and multicenter validation of on-site breast cancer diagnosis using paper spray ionization miniature mass spectrometry. [europepmc]
• Improving HER2 Diagnostics with Digital Real-Time PCR for Ultrafast, Precise Prediction of Anti-HER2 Therapy Response in Patients with Breast Cancer. [europepmc]
• Digital pathology enabling lean management of HER2/neu testing in breast Cancer. [europepmc]
• Development and multicenter external validation of an intratumoral and peritumoral ultrasound-based radiomics model for preoperative prediction of HER2 status in IHC 2 + breast cancer. [europepmc]

Related

• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update
• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
• Global Study on the Accuracy of Human Epidermal Growth Factor Receptor 2-Low Diagnosis in Breast Cancer